Argentina - español - SANI (Asociación de Cooperativas Argentinas)

ganafort - vitaminas (palmitato); vitamina d3; vitamina e (alfatocoferol); manganeso oxido manganoso mangánico; cobre oxido cúprico; hierro sulfato ferroso; cobalto carbonato; yodo yoduro de potasio; hidroxitolueno butilado (bht); calcio carbonato c.s.p. - vitaminas (palmitato) 12.000.000 u.l.; vitamina d3 2.200.ooo u.l.; vitamina e (alfatocoferol) 2.500 u.l.; manganeso oxido manganoso mangánico 48,8 g.; cobre oxido cúprico 6 g.; hierro sulfato ferroso 125 g.; cobalto carbonato 1,5 g.; yodo yoduro de potasio 0,75 g.; hidroxitolueno butilado (bht) 62,5 g.; calcio carbonato c.s.p. 5 kg. - mineralizante. vitamínico. calcio. cobre. - bovinos

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

ganafort - vitamina .a (palmitato); vitamina d3; vitamina e (alfatocoferol); vitamina b2 (fosfato de sodio riboflavina); Ácido pantoténico; niacina (Ácido nicotínico); vitamina b12 (fosfato de cianocobalamina); manganeso óxido manganoso mangánico; cobre óxido cúprico; cinc óxido de cinc; hierro sulfato ferroso; yodo yoduro de potasio; bht (hidroxitolueno butilado); cinc bacifracina cinc; carbonato de calcio c.s.p. - vitamina .a (palmitato) 4.500.000 u.l.; vitamina d3 900.000 u.l.; vitamina e (alfatocoferol) 1.200 u.l.; vitamina b2 (fosfato de sodio riboflavina) 1,5 g.; Ácido pantoténico 4,5 g.; niacina (Ácido nicotínico) 8 g.; vitamina b12 (fosfato de cianocobalamina) 41 mg.; manganeso óxido manganoso mangánico 28 g.; cobre óxido cúprico 57 g.; cinc óxido de cinc 57 g.; hierro sulfato ferroso 164 g.; yodo yoduro de potasio 0,32 g.; bht (hidroxitolueno butilado) 62,5 g.; cinc bacifracina cinc 10 g.; carbonato de calcio c.s.p. 5 kg. - mineralizante, calcio, hierro y polivitamínico. - porcinos

Unión Europea - español - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - clorhidrato de doxorrubicina - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agentes antineoplásicos - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Unión Europea - español - EMA (European Medicines Agency)

baxter holding b.v. - clorhidrato de doxorrubicina - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - agentes antineoplásicos - caelyx liposomal pegilada se indica:como monoterapia para pacientes con cáncer de mama metastásico, donde hay un aumento del riesgo cardíaco;para el tratamiento de cáncer de ovario avanzado en mujeres que no han logrado una primera línea de quimioterapia basada en platino régimen;en combinación con bortezomib para el tratamiento de la progresiva mieloma múltiple en pacientes que han recibido al menos una terapia previa y que ya han sufrido o no son adecuados para el trasplante de médula ósea;para el tratamiento de las relacionadas con el sida, el sarcoma de kaposi (sk) en pacientes con recuentos bajos de cd4 (.

Unión Europea - español - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - neoplasias pancreáticas - agentes antineoplásicos - tratamiento del adenocarcinoma metastásico del páncreas, en combinación con 5 fluorouracilo (5 fu) y leucovorina (lv), en pacientes adultos que han progresado después de la terapia basada en gemcitabina.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

kendal import s.a.c. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

american hospital scientific equipment company del peru s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

yb valdivias s.a.c. -

Unión Europea - español - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. para obtener más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (her2), consulte la sección 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. para más información sobre el estado de her2, consulte la sección 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.